GSK and Spero Therapeutics have scor | Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treatment for complicated urinary tract infections, the company and its partner GSK have pushed Utebzi across the finish line.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
In a landmark moment for its oncology ambitions, GSK has
This week on “The Top Line,” Fierce Healthcare and Life Sciences’ editor-in-chief steps behind the microphone for a solo episode…
More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery…
The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), could…
Two months after UCB revealed the success of Bimzelx in a head-to-head trial aga | Two months after UCB revealed the success of…
In what GSK says represents a potential way to transform treatment for patients with certain types of rectal cancer, the…
